

# Morphine for system suitability

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878  
Issue date: 21/06/2023 Version: 1.0

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1. Product identifier

Product form : Mixture  
Product name : Morphine for system suitability  
Product code : 202300230

#### 1.2. Relevant identified uses of the substance or mixture and uses advised against

##### 1.2.1. Relevant identified uses

Main use category : The product is intended for research, analysis and scientific education.  
Use of the substance/mixture : For professional use only  
Function or use category : Laboratory chemicals

##### 1.2.2. Uses advised against

Restrictions on use : Do not use : Ingestion, Inhalation, Dermal

#### 1.3. Details of the supplier of the safety data sheet

European Directorate for the Quality of Medicines & Healthcare  
EDQM, Council of Europe 7, Allée Kastner, CS30026  
F- 67081 Strasbourg  
France  
T +33(0)388412035 - F +33(0)388412771  
[sds@edqm.eu](mailto:sds@edqm.eu) - [www.edqm.eu](http://www.edqm.eu)

#### 1.4. Emergency telephone number

Emergency number : +33(0)390215608

### SECTION 2: Hazards identification

#### 2.1. Classification of the substance or mixture

##### Classification according to Regulation (EC) No. 1272/2008 [CLP]

|   |      |
|---|------|
| Acute toxicity (oral), Category 4                                       | H302 |
| Germ cell mutagenicity, Category 2                                      | H341 |
| Reproductive toxicity, Category 2                                       | H361 |
| Reproductive toxicity, Additional category, Effects on or via lactation | H362 |
| Specific target organ toxicity – Single exposure, Category 3, Narcosis  | H336 |
| Full text of H- and EUH-statements: see section 16                      |      |

##### Adverse physicochemical, human health and environmental effects

Expert judgement and weight of evidence determination.

#### 2.2. Label elements

##### Labelling according to Regulation (EC) No. 1272/2008 [CLP]

Hazard pictograms (CLP) :



GHS07

GHS08

Signal word (CLP) : Warning  
Contains : Morphine hydrochloride trihydrate; Oripavine; Morphinone; Morphine N-oxide  
Hazard statements (CLP) : H302 - Harmful if swallowed.  
H336 - May cause drowsiness or dizziness.  
H341 - Suspected of causing genetic defects.  
H361 - Suspected of damaging fertility or the unborn child.  
H362 - May cause harm to breast-fed children.

# Morphine for system suitability

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

Precautionary statements (CLP) : P201 - Obtain special instructions before use.  
P202 - Do not handle until all safety precautions have been read and understood.  
P260 - Do not breathe dust/fume/gas/mist/vapours/spray.  
P263 - Avoid contact during pregnancy and while nursing.  
P264 - Wash hands, forearms and face thoroughly after handling.  
P270 - Do not eat, drink or smoke when using this product.  
P271 - Use only outdoors or in a well-ventilated area.  
P280 - Wear protective gloves/protective clothing/eye protection/face protection/hearing protection.  
P301+P312 - IF SWALLOWED: Call a POISON CENTRE or doctor if you feel unwell.  
P304+P340 - IF INHALED: Remove person to fresh air and keep comfortable for breathing.  
P308+P313 - IF exposed or concerned: Get medical advice/attention.  
P312 - Call a POISON CENTRE or doctor if you feel unwell.  
P330 - Rinse mouth.  
P403+P233 - Store in a well-ventilated place. Keep container tightly closed.  
P405 - Store locked up.  
P501 - Dispose of contents/container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulation.

EUH-statements : EUH208 - Contains Oripavine, Morphinone, Morphine N-oxide. May produce an allergic reaction.

Labelling according to: exemption for inner packaging where the contents do not exceed 10ml

Hazard pictograms (CLP) :



GHS08

Hazardous ingredients : Morphine hydrochloride trihydrate; Oripavine; Morphinone; Morphine N-oxide

### 2.3. Other hazards

Contains no PBT/vPvB substances  $\geq 0.1\%$  assessed in accordance with REACH Annex XIII

The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %

## SECTION 3: Composition/information on ingredients

### 3.1. Substances

Not applicable

### 3.2. Mixtures

| Name                              | Product identifier | %          | Classification according to Regulation (EC) No. 1272/2008 [CLP]  |
|-----------------------------------|--------------------|------------|--|
| Morphine hydrochloride trihydrate | -                  | $\leq 100$ | Acute Tox. 4 (Oral), H302 (ATE=335 mg/kg bodyweight)<br>Muta. 2, H341<br>Repr. 2, H361<br>Lact., H362<br>STOT SE 3, H336 |

# Morphine for system suitability

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

| Name             | Product identifier | %     | Classification according to Regulation (EC) No. 1272/2008 [CLP]   |
|------------------|--------------------|-------|---|
| Oripavine        | -                  | ≤ 0,2 | Acute Tox. 3 (Oral), H301 (ATE=100 mg/kg bodyweight)<br>Acute Tox. 3 (Dermal), H311 (ATE=300 mg/kg bodyweight)<br>Acute Tox. 3 (Inhalation), H331 (ATE=0,5 mg/l/4h)<br>Resp. Sens. 1, H334<br>Skin Sens. 1, H317<br>Repr. 2, H361 |
| Morphinone       | -                  | ≤ 0,2 | Acute Tox. 3 (Oral), H301 (ATE=100 mg/kg bodyweight)<br>Acute Tox. 3 (Inhalation), H331 (ATE=0,5 mg/l/4h)<br>Resp. Sens. 1, H334<br>Skin Sens. 1, H317  |
| Morphine N-oxide | -                  | ≤ 0,2 | Acute Tox. 3 (Oral), H301 (ATE=100 mg/kg bodyweight)<br>Acute Tox. 3 (Inhalation), H331 (ATE=0,5 mg/l/4h)<br>Resp. Sens. 1, H334<br>Skin Sens. 1, H317<br>Repr. 2, H361fd<br>Lact., H362  |

Full text of H- and EUH-statements: see section 16

## SECTION 4: First aid measures

### 4.1. Description of first aid measures

First-aid measures after skin contact : Wipe off as much as possible (using a clean, soft, absorbent material).  
First-aid measures after eye contact : Rinse eyes with water as a precaution.

### 4.2. Most important symptoms and effects, both acute and delayed

No additional information available

### 4.3. Indication of any immediate medical attention and special treatment needed

No additional information available

## SECTION 5: Firefighting measures

### 5.1. Extinguishing media

Suitable extinguishing media : Extinguishing blanket.

### 5.2. Special hazards arising from the substance or mixture

Fire hazard : See Heading 2.2.

### 5.3. Advice for firefighters

Firefighting instructions : Use extinguishing media appropriate for surrounding fire.

# Morphine for system suitability

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

### SECTION 6: Accidental release measures

#### 6.1. Personal precautions, protective equipment and emergency procedures

##### 6.1.1. For non-emergency personnel

Emergency procedures : Avoid all unnecessary exposure.

##### 6.1.2. For emergency responders

No additional information available

#### 6.2. Environmental precautions

No additional information available

#### 6.3. Methods and material for containment and cleaning up

No additional information available

#### 6.4. Reference to other sections

No additional information available

### SECTION 7: Handling and storage

#### 7.1. Precautions for safe handling

No additional information available

#### 7.2. Conditions for safe storage, including any incompatibilities

No additional information available

#### 7.3. Specific end use(s)

See Heading 1.

### SECTION 8: Exposure controls/personal protection

#### 8.1. Control parameters

##### 8.1.1 National occupational exposure and biological limit values

No additional information available

##### 8.1.2. Recommended monitoring procedures

No additional information available

##### 8.1.3. Air contaminants formed

No additional information available

##### 8.1.4. DNEL and PNEC

No additional information available

##### 8.1.5. Control banding

No additional information available

#### 8.2. Exposure controls

##### 8.2.1. Appropriate engineering controls

###### Appropriate engineering controls:

Keep in a well-ventilated room. Both local exhaust and general room ventilation are usually required.

##### 8.2.2. Personal protection equipment

###### 8.2.2.1. Eye and face protection

No additional information available

# Morphine for system suitability

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

### 8.2.2.2. Skin protection

#### Skin and body protection:

Lab coat

#### Hand protection:

Protective gloves

### 8.2.2.3. Respiratory protection

No additional information available

### 8.2.2.4. Thermal hazards

No additional information available

### 8.2.3. Environmental exposure controls

No additional information available

## SECTION 9: Physical and chemical properties

### 9.1. Information on basic physical and chemical properties

|   |                  |
|---|------------------|
| Physical state                                  | : Solid          |
| Colour  | : Not available  |
| Odour   | : Not available  |
| Odour threshold                                 | : Not available  |
| Melting point                                   | : Not available  |
| Freezing point                                  | : Not available  |
| Boiling point                                   | : Not available  |
| Flammability                                    | : Not available  |
| Explosive limits                                | : Not applicable |
| Lower explosion limit                           | : Not applicable |
| Upper explosion limit                           | : Not applicable |
| Flash point                                     | : Not applicable |
| Auto-ignition temperature                       | : Not applicable |
| Decomposition temperature                       | : Not available  |
| pH  | : Not available  |
| pH solution                                     | : Not available  |
| Viscosity, kinematic                            | : Not applicable |
| Solubility                                      | : Not available  |
| Partition coefficient n-octanol/water (Log Kow) | : Not available  |
| Vapour pressure                                 | : Not available  |
| Vapour pressure at 50°C                         | : Not available  |
| Density   | : Not available  |
| Relative density                                | : Not available  |
| Relative vapour density at 20°C                 | : Not applicable |
| Particle size                                   | : Not available  |

### 9.2. Other information

#### 9.2.1. Information with regard to physical hazard classes

No additional information available

#### 9.2.2. Other safety characteristics

No additional information available

## SECTION 10: Stability and reactivity

### 10.1. Reactivity

Stable under normal conditions.

# Morphine for system suitability

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

### 10.2. Chemical stability

No additional information available

### 10.3. Possibility of hazardous reactions

None known.

### 10.4. Conditions to avoid

No additional information available

### 10.5. Incompatible materials

None under normal use. See Section 7.

### 10.6. Hazardous decomposition products

When heated to decomposition, emits dangerous fumes.

## SECTION 11: Toxicological information

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

|                             |   |
|-----------------------------|---|
| Acute toxicity (oral)       | : Harmful if swallowed.   |
| Acute toxicity (dermal)     | : Not classified (Based on available data, the classification criteria are not met) |
| Acute toxicity (inhalation) | : Not classified (Based on available data, the classification criteria are not met) |

#### Morphine for system suitability

|                |                          |
|----------------|--------------------------|
| ATE CLP (oral) | 331,264 mg/kg bodyweight |
|----------------|--------------------------|

#### Morphine hydrochloride trihydrate

|               |                             |
|---------------|-----------------------------|
| LD50 oral rat | 335 mg/kg RTECS : QC8590000 |
|---------------|-----------------------------|

#### Oripavine

|                                   |                  |
|-----------------------------------|------------------|
| LD50 oral rat                     | 50 – 100 mg/kg   |
| LD50 dermal rat                   | 200 – 1000 mg/kg |
| LC50 Inhalation - Rat (Dust/Mist) | 0,5 – 1 mg/l/4h  |

#### Morphine N-oxide

|                                   |                 |
|-----------------------------------|-----------------|
| LD50 oral rat                     | 50 – 300 mg/kg  |
| LC50 Inhalation - Rat (Dust/Mist) | 0,5 – 1 mg/l/4h |

|                                   |   |
|-----------------------------------|---|
| Skin corrosion/irritation         | : Not classified (Based on available data, the classification criteria are not met)           |
| Serious eye damage/irritation     | : Not classified (Based on available data, the classification criteria are not met)           |
| Respiratory or skin sensitisation | : Not classified (Based on available data, the classification criteria are not met)           |
| Germ cell mutagenicity            | : Suspected of causing genetic defects.   |
| Carcinogenicity                   | : Not classified (Based on available data, the classification criteria are not met)           |
| Reproductive toxicity             | : Suspected of damaging fertility or the unborn child. May cause harm to breast-fed children. |
| STOT-single exposure              | : May cause drowsiness or dizziness.  |

#### Morphine hydrochloride trihydrate

|                      |                                    |
|----------------------|------------------------------------|
| STOT-single exposure | May cause drowsiness or dizziness. |
|----------------------|------------------------------------|

|                        |   |
|------------------------|---|
| STOT-repeated exposure | : Not classified (Based on available data, the classification criteria are not met) |
| Aspiration hazard      | : Not classified (Based on available data, the classification criteria are not met) |

### 11.2. Information on other hazards

No additional information available

# Morphine for system suitability

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

### SECTION 12: Ecological information

#### 12.1. Toxicity

Ecology - general : Presents no specific risk for the environment.  
Hazardous to the aquatic environment, short-term (acute) : Not classified (Based on available data, the classification criteria are not met)  
Hazardous to the aquatic environment, long-term (chronic) : Not classified (Based on available data, the classification criteria are not met)  
Not rapidly degradable

#### 12.2. Persistence and degradability

No additional information available

#### 12.3. Bioaccumulative potential

No additional information available

#### 12.4. Mobility in soil

No additional information available

#### 12.5. Results of PBT and vPvB assessment

No additional information available

#### 12.6. Endocrine disrupting properties

No additional information available

#### 12.7. Other adverse effects

No additional information available

### SECTION 13: Disposal considerations

#### 13.1. Waste treatment methods

No additional information available

### SECTION 14: Transport information

In accordance with ADR / IMDG / IATA

| ADR                                     | IMDG           | IATA           |
|---|----------------|----------------|
| <b>14.1. UN number or ID number</b>     |                |                |
| Not applicable                          | Not applicable | Not applicable |
| <b>14.2. UN proper shipping name</b>    |                |                |
| Not applicable                          | Not applicable | Not applicable |
| <b>14.3. Transport hazard class(es)</b> |                |                |
| Not applicable                          | Not applicable | Not applicable |
| <b>14.4. Packing group</b>              |                |                |
| Not applicable                          | Not applicable | Not applicable |
| <b>14.5. Environmental hazards</b>      |                |                |
| Not applicable                          | Not applicable | Not applicable |
| No supplementary information available  |                |                |

# Morphine for system suitability

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

### 14.6. Special precautions for user

#### Overland transport

Not applicable

#### Transport by sea

Not applicable

#### Air transport

Not applicable

### 14.7. Maritime transport in bulk according to IMO instruments

Not applicable

## SECTION 15: Regulatory information

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### 15.1.1. EU-Regulations

##### REACH Annex XVII (Restriction List)

Contains no substance(s) listed on REACH Annex XVII (Restriction Conditions)

##### REACH Annex XIV (Authorisation List)

Contains no substance(s) listed on REACH Annex XIV (Authorisation List)

##### REACH Candidate List (SVHC)

Contains no substance(s) listed on the REACH Candidate List

##### PIC Regulation (Prior Informed Consent)

Not applicable.

##### POP Regulation (Persistent Organic Pollutants)

Not applicable.

##### Ozone Regulation (1005/2009)

Contains no substance(s) listed on the Ozone Depletion list (Regulation EU 1005/2009 on substances that deplete the ozone layer)

##### Explosives Precursors Regulation (2019/1148)

Contains no substance(s) listed on the Explosives Precursors list (Regulation EU 2019/1148 on the marketing and use of explosives precursors)

##### Drug Precursors Regulation (273/2004)

Contains no substance(s) listed on the Drug Precursors list (Regulation EC 273/2004 on the manufacture and the placing on market of certain substances used in the illicit manufacture of narcotic drugs and psychotropic substances)

#### 15.1.2. National regulations

No additional information available

### 15.2. Chemical safety assessment

No additional information available

## SECTION 16: Other information

### Full text of H- and EUH-statements:

|                           |                                     |
|---------------------------|-------------------------------------|
| Acute Tox. 3 (Dermal)     | Acute toxicity (dermal), Category 3 |
| Acute Tox. 3 (Inhalation) | Acute toxicity (inhal.), Category 3 |
| Acute Tox. 3 (Oral)       | Acute toxicity (oral), Category 3   |
| Acute Tox. 4 (Oral)       | Acute toxicity (oral), Category 4   |



# Morphine for system suitability

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

| Full text of H- and EUH-statements: |   |
|-------------------------------------|---|
| EUH208                              | Contains Oripavine, Morphinone, Morphine N-oxide. May produce an allergic reaction. |
| H301                                | Toxic if swallowed.   |
| H302                                | Harmful if swallowed.   |
| H311                                | Toxic in contact with skin.   |
| H317                                | May cause an allergic skin reaction.  |
| H331                                | Toxic if inhaled.   |
| H334                                | May cause allergy or asthma symptoms or breathing difficulties if inhaled.          |
| H336                                | May cause drowsiness or dizziness.  |
| H341                                | Suspected of causing genetic defects.   |
| H361                                | Suspected of damaging fertility or the unborn child.                                |
| H361fd                              | Suspected of damaging fertility. Suspected of damaging the unborn child.            |
| H362                                | May cause harm to breast-fed children.  |
| Lact.                               | Reproductive toxicity, Additional category, Effects on or via lactation             |
| Muta. 2                             | Germ cell mutagenicity, Category 2  |
| Repr. 2                             | Reproductive toxicity, Category 2   |
| Resp. Sens. 1                       | Respiratory sensitisation, Category 1   |
| Skin Sens. 1                        | Skin sensitisation, Category 1  |
| STOT SE 3                           | Specific target organ toxicity – Single exposure, Category 3, Narcosis              |

| Classification and procedure used to derive the classification for mixtures according to Regulation (EC) 1272/2008 [CLP]: |      |                    |
|---|------|--------------------|
| Acute Tox. 4 (Oral)   | H302 | Calculation method |
| Muta. 2   | H341 | Calculation method |
| Repr. 2   | H361 | Calculation method |
| Lact.   | H362 | Calculation method |
| STOT SE 3   | H336 | Calculation method |

Safety Data Sheet (SDS), EU

DISCLAIMER OF LIABILITY The EDQM has created this SDS as a downstream user for regulatory compliance to rules applicable to chemicals only. This article is intended only for small-volume laboratory analysis and other routine testing prescribed in the pharmacopoeia or EDQM study protocol, under controlled conditions and by professionals only. Any other use of this article or the SDS information is the sole responsibility of the user. This substance is present in articles in quantities totalling under 10 kg per year. There is no human or environmental exposure under intended and foreseeable conditions of use. The user has the responsibility for handling, storage, use conditions and disposal of this article and for any use of the information in this SDS. The information has been obtained from suppliers and is without any warranty, express or implied, regarding its correctness. For this and other reasons, we do not assume responsibility and expressly disclaim liability for loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of the article.